What is the recommended dosing and safety information for Betahistine dehydrochloride 8 mg tablets for vertigo due to Ménière’s disease?

Betahistine Dehydrochloride 8 mg for Ménière's Disease

Based on the highest quality evidence from the 2020 BEMED trial, betahistine (including the 8 mg dose) does not reduce vertigo attacks in Ménière's disease compared to placebo, and current guidelines cannot make a definitive recommendation for its use. 1

Evidence Summary

Efficacy Data

The most rigorous evidence comes from the BEMED trial, a well-designed double-blind RCT that tested low-dose betahistine (48 mg/day, equivalent to 8 mg three times daily), high-dose (144 mg/day), and placebo over 9 months. All three groups showed significant decline in vertigo attacks, but there were no significant differences between betahistine and placebo groups at 7-9 months. 1

This contradicts older, lower-quality studies that suggested benefit. The 2020 AAO-HNS Clinical Practice Guideline explicitly states: "Currently, this CPG committee is unable to make a definitive statement on use of betahistine to control MD symptoms." 1

Dosing Information (When Used Despite Limited Evidence)

When betahistine is prescribed:

• Standard dose: 8 mg three times daily (24-48 mg/day total)
• Duration: Most studies evaluated 2-12 weeks; the BEMED trial used 9 months 1
• Titration: Clinicians should discuss tapering or stopping once symptoms subside, though optimal duration is unclear 1
• Monitoring: Reassess as clinically warranted for symptom improvement/stabilization and medication tolerance 1

Safety Profile

Betahistine is generally well-tolerated with rare serious adverse effects. 1

Common side effects include:

• Headache
• Balance disorder
• Nausea
• Nasopharyngitis
• Feeling hot
• Eye irritation
• Palpitations
• Upper gastrointestinal symptoms 1

Contraindications and Precautions:

• Avoid in patients with pheochromocytoma 1
• Use with caution in:
  • Asthma or bronchial hyperactivity 1
  • History of peptic ulcer disease 1

Clinical Decision Algorithm

1. First-line approach: Lifestyle modifications (dietary changes, salt restriction) remain the foundation of Ménière's disease management 1

2. If lifestyle measures fail: Consider that betahistine may be prescribed despite limited evidence, acknowledging:

   • No proven superiority over placebo for vertigo control
   • Excellent safety profile
   • Widespread historical use (>150 million patients treated) 2

3. If prescribing betahistine 8 mg:

   • Start with 8 mg three times daily
   • Trial period of 2-3 months minimum
   • Monitor for symptom improvement and adverse effects
   • Consider discontinuation if no benefit after adequate trial

4. If inadequate response: Progress to intratympanic steroids or other interventions rather than increasing betahistine dose indefinitely 1

Important Caveats

The disconnect between widespread use and evidence: Despite betahistine being approved in >80 countries and used for decades, the highest quality modern evidence does not support its efficacy. The natural history of Ménière's disease includes spontaneous improvement in up to 60% of patients, which may explain perceived benefits in uncontrolled observations. 1

Bioavailability concerns: Recent research suggests betahistine has extremely low bioavailability when used alone, which may explain the lack of efficacy at standard doses. 3

The 8 mg dose specifically represents the lower end of the therapeutic range and is unlikely to provide benefit based on current evidence, though it carries minimal risk.